Argyle Capital Partners’s Pfizer PFE Stock Holding History

Argyle Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Buy	14,510 +606	+4%	+$16.1K	0.29%	96
2025 Q4	$346K	Buy	13,904 +1,261	+10%	+$31.8K	0.25%	105
2025 Q3	$322K	Sell	12,643 -1,330	-10%	-$32.8K	0.23%	121
2025 Q2	$339K	Buy	13,973 +1,686	+14%	+$39.3K	0.28%	102
2025 Q1	$311K	Sell	12,287 -1,795	-13%	-$47K	0.27%	99
2024 Q4	$374K	Buy	+14,082	New	+$382K	0.32%	89

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Argyle Capital Partners's PFE Position: Q1 2026 in Review

Argyle Capital Partners increased its Pfizer (PFE) stake by 4.4% in Q1 2026, buying an estimated $16.1K and bringing the position to 14,510 shares worth $407K. The position accounts for 0.29% of the portfolio, ranked #96.

Argyle Capital Partners first reported a position in PFE in Q4 2024 and has held it in 6 quarters since. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Argyle Capital Partners held 14,510 shares of Pfizer worth $407K as of Q1 2026.
Argyle Capital Partners bought 606 Pfizer shares in Q1 2026, an estimated $16.1K.
Pfizer made up 0.29% of Argyle Capital Partners's portfolio in Q1 2026, its #96 holding.
Argyle Capital Partners first reported a position in Pfizer in Q4 2024 and has held it in 6 quarters since.
2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Argyle Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.